3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Prostatic Neoplasms
9
Leukemia, Myeloid, Acute
9
Endometrial Neoplasms
8
Breast Neoplasms
7
Oropharyngeal Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Lung Neoplasms
5
Colonic Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Multiple Myeloma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia, Erythroblastic, Acute
4
Congenital Abnormalities
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Rectal Neoplasms
3
Neuroblastoma
3
Mouth Neoplasms
3
Lymphoma, Follicular
3
Leukemia
3
Esophageal Neoplasms
3
Brain Neoplasms
3
Interventions
Cisplatin
16
Cetuximab
16
Radiotherapy, Intensity-Modulated
10
Radiotherapy
7
Docetaxel
7
Fluorouracil
5
Erlotinib Hydrochloride
5
Everolimus
4
Carboplatin
4
Sorafenib
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Chemotherapy, Adjuvant
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
Ultrasonography
2
Taxes
2
Sirolimus
2
Radiotherapy, Conformal
2
Radiation
2
Platinum
2
Photochemotherapy
2
Magnetic Resonance Spectroscopy
2
Cryosurgery
2
Celecoxib
2
Biopsy
2
Bevacizumab
2
1-phenyl-3,3-dimethyltriazene
2
1,2-diaminocyclohexaneplatinum II citrate
2
temsirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tongue Neoplasms
×
Observation
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled